FOUNDER, CEO, BIONIZ THERAPEUTICS
WHY: Runs medical research firm backed by David Pyott, former CEO of Allergan, and Joe Kiani, founder and CEO of Masimo.
RECENT: Pharmaceutical firm Almirall made a $15M upfront payment for exclusive rights to Bioniz’s BNZ-1, an inhibitor that is being tested for its ability to fight a type of lymphoma, in January. The deal could ultimately result in a $540M sale.
QUOTABLE: “The beauty of the deal that was very important was it didn’t require the full acquisition of our portfolio,” Azimi said. “We will continue with other programs.”
